What are the SSF guidelines indications for the use of rituximab in the treatment of Sjögren syndrome?

Updated: Mar 05, 2021
  • Author: Sriya K Ranatunga, MD, MPH; Chief Editor: Herbert S Diamond, MD  more...
  • Print

Rituximab may be considered as a therapeutic option for the following indications in patients with primary Sjögren syndrome:

  • Keratoconjunctivitis sicca (KCS), in patients for whom conventional therapies (eg, topical moisturizers, secretagogues, anti-inflammatory drugs, immunomodulators, punctual occlusion) have proven insufficient
  • Xerostomia, in patients with primary Sjögren syndrome with some evidence of residual salivary production and clinician-determined significant evidence of oral damage, in whom conventional therapies, including topical moisturizers and secretagogues, have proved insufficient

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!